HOWL Key Statistics, Chart & Performance
The current stock price of HOWL is 0.5493 USD. In the past month the price decreased by -48.66%. In the past year, price decreased by -58.7%.
HOWL Technical Analysis
HOWL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HOWL. HOWL has a bad profitability rating. Also its financial health evaluation is rather negative.
HOWL Financial Highlights
Over the last trailing twelve months HOWL reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS decreased by -8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.48% | ||
| ROE | -245.97% | ||
| Debt/Equity | 0.73 |
HOWL Forecast & Estimates
12 analysts have analysed HOWL and the average price target is 5.3 USD. This implies a price increase of 865.59% is expected in the next year compared to the current price of 0.5493.
For the next year, analysts expect an EPS growth of 4.88% and a revenue growth -100% for HOWL
HOWL Ownership
HOWL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About HOWL
Company Profile
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
Company Info
WEREWOLF THERAPEUTICS INC
200 Talcott Avenue, 2nd Floor
Watertown MASSACHUSETTS 02138 US
CEO: Daniel J. Hicklin
Employees: 46
Phone: 16179520555
WEREWOLF THERAPEUTICS INC / HOWL FAQ
What does WEREWOLF THERAPEUTICS INC do?
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
Can you provide the latest stock price for WEREWOLF THERAPEUTICS INC?
The current stock price of HOWL is 0.5493 USD. The price decreased by -0.29% in the last trading session.
Does WEREWOLF THERAPEUTICS INC pay dividends?
HOWL does not pay a dividend.
How is the ChartMill rating for WEREWOLF THERAPEUTICS INC?
HOWL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in WEREWOLF THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HOWL.
Can you provide the market cap for WEREWOLF THERAPEUTICS INC?
WEREWOLF THERAPEUTICS INC (HOWL) has a market capitalization of 26.66M USD. This makes HOWL a Nano Cap stock.
Can you provide the ownership details for HOWL stock?
You can find the ownership structure of WEREWOLF THERAPEUTICS INC (HOWL) on the Ownership tab.